Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin in patients with hematologic malignancies
2009-014527-23Phase 2Completed
- Sponsor
- Elisabethinen Linz
- Start
- Sep 2009
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anidulafungin in invasive mycoses and hematopoietic malignancies, sponsored by Elisabethinen Linz. Primary endpoint: Safety (adverse events and laboratory changes). Started Sep 2009; status: completed.
02
Drugs
anidulafungin
03
Conditions
invasive mycoseshematopoietic malignancies
Beyond the preview
Go deeper on 2009-014527-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014527-23.